Q-Line Biotech IPO
Live SMEAlready have an account? Apply now
Q-Line Biotech IPO details
Schedule of Q-Line Biotech
| Issue open date | 21 May 2026 |
| Issue close date | 25 May 2026 |
| UPI mandate deadline | 25 May 2026 (5 PM) |
| Allotment finalization | 26 May 2026 |
| Refund initiation | 27 May 2026 |
| Share credit | 27 May 2026 |
| Listing date | 29 May 2026 |
| Mandate end date | 09 Jun 2026 |
| Lock-in end date for anchor investors (50%) | 24 Jun 2026 |
| Lock-in end date for anchor investors (remaining) | 23 Aug 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Q-Line Biotech
Q-Line Biotech Limited is an in-vitro diagnostics (IVD) company engaged in the manufacturing and trading of biochemistry reagents, diagnostic instruments and consumables used in healthcare testing and laboratory applications. The company operates multiple manufacturing facilities in Uttar Pradesh and Delhi and offers products across categories such as ELISA, molecular diagnostics, chemiluminescence immunoassay (CLIA), immuno fluorescence assay (IFA), nucleic acid extraction kits and PCR-based diagnostic kits. Its product portfolio includes tests for infectious diseases, thyroid disorders, cardiac markers and other clinical conditions. The company generates revenue primarily through the sale of its diagnostic products and instruments, largely through a network of distributors, including group entity POCT Services. Q-Line Biotech also focuses on research and development through its subsidiary, Q-Line Innovations Private Limited, which works on developing diagnostic and scientific equipment and consumables.
Financials of Q-Line Biotech
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 214.48 |
| Fresh Issue – Proceeds go to the company | 214.48 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Working capital requirements | 93.5 (43.59%) |
| Repayment of borrowings | 90 (41.96%) |
| General corporate purposes | 30.98 (14.45%) |
Strengths
- Q-Line Biotech has established manufacturing capabilities with a focus on R&D and quality control.
- The company offers a diversified product portfolio across multiple IVD segments.
- It has a widespread distribution network across all four regions of India.
- The company has long-standing relationships with customers in the diagnostics industry.
- Q-Line Biotech has shown a track record of healthy financial performance.
Risks
- Any disruption at its manufacturing or R&D facilities could affect operations and revenue.
- The company depends on third-party suppliers for key raw materials and equipment.
- A large share of revenue comes from a few major customers.
- Failure to maintain product quality could lead to recalls, penalties, or reputational damage.
- Delays in regulatory approvals or registrations may impact business operations.
Subscription Figures for Q-Line Biotech
As per media reports (Link), the Grey Market Premium (GMP) of Q-Line Biotech is reported at ₹120 over the IPO price. This metric is unreliable; to track IPO interest, it is better to check subscription numbers published by exchanges, which are considered more reliable indicators.
Subscription numbers as of 05:00 PM on May 22, 2026:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 11.88 | 61.64 | 5.19x |
| NII | 8.92 | 139.22 | 15.61x |
| Retail | 20.79 | 208.32 | 10.02x |
| Total | 41.59 | 409.18 | 9.84x |